Novo and Lilly’s campaigns are not limited to advertisements alone, and both companies are trying to raise awareness around obesity through research studies and conferences.

Megastar Chiranjeevi expressed his gratitude and enthusiasm upon receiving the UK's Lifetime Achievement Award, stating that ...

“While (Eli Lilly’s ) injectables have got approval ... sales of these drugs will happen only by mid-2025," informs Mumbai-based Dr Rajiv Kovil, head of diabetology at Zandra Healthcare.

Spooked by US president's threat, several Indian pharma players lobby for blanket duty waiver on drugs coming from America, ...

India's largest drugmaker by revenue Sun Pharmaceutical is aiming to launch its experimental anti-obesity and type 2 diabetes drug in the next four to five years, Managing Director Dilip Shanghvi said ...

“We are also keenly looking at it," Majumdar, who leads the company’s specialty division out of Mumbai, said ... Innovator Eli Lilly, whose weight loss drug Tirzepatide is sold under brand ...

And they represent every vertical and horizontal one can think of—from the large financial companies, with their massive centres, to drug companies such as Novo Nordisk and Eli Lilly—which has ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Eli Lilly's much-anticipated drug for diabetes and obesity, that competes with Ozempic globally, is now in India. Here's what ...

Eli Lilly (LLY) stock in focus as the company launches its weight loss therapy Mounjaro in India, beating its rival Novo Nordisk (NVO). Read more here.

The drug, typically taken once a week, would cost between Rs 14,000 and Rs 17,500 per month, depending on the dosage ...